Legend Biotech (NASDAQ:LEGN – Free Report) had its target price raised by Barclays from $92.00 to $93.00 in a research report sent to investors on Wednesday, Benzinga reports. Barclays currently has an overweight rating on the stock. Several other research firms have also weighed in on LEGN. Morgan Stanley lifted their target price on shares […]
Mach 1 Financial Group LLC purchased a new stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,702 shares of the company’s stock, valued at approximately $463,000. A number of other institutional investors […]
Clough Capital Partners L P lifted its stake in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 423.0% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 201,236 shares of the company’s stock after purchasing an additional 162,760 shares during the period. Clough Capital Partners L P’s holdings in Legend Biotech were […]
Krane Funds Advisors LLC grew its stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 1.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 22,691 shares of the company’s stock after buying an additional 262 shares during the quarter. Krane […]
Legend Biotech (NASDAQ:LEGN – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.21), MarketWatch Earnings reports. The firm had revenue of $73.30 million for the quarter, compared to analysts’ expectations of $56.64 million. The business’s revenue for the […]